VivoSeq
Oncology

Cancer (solid Tumors)

1

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Cancer (Solid Tumors) is an early-stage landscape with 1 program across 2 companies. The most active players are Boehringer Ingelheim, Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI).

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalC

Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Dexamethasone Sparing

Mahidol University

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting2 · 29%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study
Recruiting·MMahidol University·Phase 2·NCT07699276·95 enrolled
Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
Recruiting·CCentre Mohammed VI de la Recherche et de l'Innovation (CM6RI)·N/A·NCT07670234·1,000 enrolled
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Not yet recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT07395258·60 enrolled
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03964233·119 enrolled
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03449381·266 enrolled
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT04147234·42 enrolled
A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT04653142·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)